Novartis AG Price to Free Cash Flow Ratio 2006-2018 | NVS

Historical price to free cash flow ratio values for Novartis AG (NVS) since 2006.
Novartis AG Annual Price-FCF Ratio
Novartis AG Quarterly Price-FCF Ratio
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $197.053B $49.109B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $377.055B 18.02
Pfizer (PFE) United States $259.009B 15.16
Merck (MRK) United States $189.866B 16.77
AbbVie (ABBV) United States $140.237B 13.70
Novo Nordisk (NVO) Denmark $115.897B 18.53
Eli Lilly (LLY) United States $114.788B 21.25
Sanofi (SNY) France $110.256B 13.96
Bristol-Myers Squibb (BMY) United States $100.491B 18.19
GlaxoSmithKline (GSK) United Kingdom $98.280B 13.12
AstraZeneca (AZN) United Kingdom $94.958B 10.44